Latest FDA‐approved drug nirsevimab‐alip (Beyfortus): A gamechanger for treatment of respiratory syncytial virus
Author:
Affiliation:
1. Department of Pediatrics Shaikh Khalifa Bin Zayed Al‐Nahyan Medical and Dental College Lahore Pakistan
Publisher
Wiley
Subject
Infectious Diseases,Virology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.29169
Reference6 articles.
1. FDA.FDA Approves New Drug to Prevent RSV in Babies and Toddlers FDA; 2023. Accessed July 19 2023.https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers
2. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study
3. Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants
4. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children
5. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. CDC changes recommendations due to severe nirsevimab shortage during the 2023−2024 RSV season;Pediatric Pulmonology;2024-01-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3